RecruitingNCT07278700

The Fever Clinic Acute Respiratory Cohort

The Fever Clinic Acute Respiratory Cohort (FACTS): A Prospective Real-World Cohort Study of Patients Presenting to Fever Clinics: Clinical Features, Laboratory and Radiographic Findings, and Long-Term Outcomes of Acute Respiratory Infections

Sponsor

Fudan University

Enrollment

1,000 participants

Start Date

Oct 10, 2025

Study Type

OBSERVATIONAL

Conditions

Community-acquired Pneumonia Febrile Illnesses Viral Respiratory Tract Infections Acute Respiratory Infections

Summary

This prospective cohort study aims to characterize the natural progression and outcomes of acute respiratory infections among patients presenting to fever clinics. At enrollment, patients' clinical symptoms, laboratory findings, and chest imaging data will be collected. Longitudinal follow-up will be conducted to evaluate disease progression, complications, and long-term outcomes. As an observational study, no interventions are involved; all patients receive routine clinical management as directed by their attending physicians. This real-world study design enables the assessment of the natural course of acute respiratory infections and the identification of factors associated with clinical outcomes.

Eligibility

Min Age: 18 Years

Inclusion Criteria5

Age ≥ 18 years (based on official identification document).
Presence of fever at the time of visit or within 24 hours prior to the visit, defined as a documented temperature of ≥37.3°C axillary/tympanic, ≥37.8°C orally, or ≥38.0°C rectally.
The primary cause of fever, as determined by the attending physician, is a respiratory tract infection.
Blood draw is required as part of standard clinical care.
Ability to comprehend the study's purpose, procedures, and potential risks, and willingness to provide written informed consent.

Exclusion Criteria4

Inability to provide independent informed consent due to impaired consciousness or other reasons.
Inability to comply with the study procedures.
Medical contraindications to blood sampling, such as severe coagulopathy (e.g., INR \> 3.0, platelet count \< 50 × 10⁹/L).
Diagnosed with a terminal illness (e.g., advanced malignancy, severe multiple organ failure) and a life expectancy of less than 3 months.

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.